BILL ANALYSIS

HR8261

NEUTRAL

To amend title XVIII of the Social Security Act to remove cost-sharing responsibilities for chronic care management services under the Medicare program.

HR8261 (To amend title XVIII of the Social Security Act to remove cost-sharing responsibilities for chronic care management services under the Medicare program.) carries an AI-assessed market impact score of 4/10 with a neutral outlook for investors. This legislation directly affects CVS Health ($CVS). The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

4/10

Impact Score

neutral

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR8261 removes Medicare beneficiary cost-sharing for chronic care management services; no direct funding, no payment rate changes.

Bill is at earliest legislative stage with only one cosponsor; passage probability is low in standalone form.

Medicare Advantage insurers with owned primary care (UNH, CVS, HUM) see a small volume tailwind if enacted; no ticker moves more than 1-2% on this alone.

Effective date of Jan 1, 2027 makes this a 'wait and see' for inclusion in year-end healthcare extenders legislation.

Zero direct appropriation means no revenue guarantee for any company; impact is entirely utilization-driven.

How HR8261 Affects the Market

No market-moving catalysts from this bill in its current state. The most relevant publicly traded names — Humana (HUM, highest Medicare Advantage concentration) and UnitedHealth Group (UNH, largest CCM billing entity via Optum) — would see a low-single-digit percentage volume tailwind if the bill becomes law. That is not actionable at this stage. Track committee assignments: if Ways and Means schedules a hearing, that signals momentum. Otherwise, this is legislative noise for retail investors. The presidential memoranda on petroleum production and Air Force training operations are unrelated to this healthcare bill and do not amplify or conflict with it.

Bill Details

Metric	Value
Bill Number	HR8261
Impact Score	4/10Certainty: Committee hearing · Financial Magnitude: $4.5B — significant funding · Strategic Weight: AI qualitative assessment: 2/10 · Market Penetration: 1 company directly affected
Market Sentiment	neutral
Event Date	April 14, 2026
Affected Sectors	Healthcare
Affected Stocks	CVS Health ($CVS)
Source	View on Congress.gov →

Summary

HR8261, the Chronic Care Management Improvement Act of 2026, is an early-stage House bill that would eliminate Medicare beneficiary cost-sharing for chronic care management services starting January 2027. The bill has zero direct federal spending (it amends coinsurance rules, not payment rates) and just one cosponsor. Market impact is minimal at this procedural stage; the structural effect would be a modest volume boost for Medicare Advantage insurers and primary care providers with chronic care management programs.

Full AI Market Analysis

1) What happened: On April 14, 2026, Representative DelBene (D-WA) introduced HR8261 with one cosponsor (Rep. Kelly, R-PA). The bill amends Section 1833 of the Social Security Act to remove the Part B deductible and 20% coinsurance for chronic care management (CCM) services, effective January 1, 2027. The bill was referred to both the Energy and Commerce and Ways and Means Committees. This is a standard early-stage referral — no hearings, no markup, no CBO score yet. The bipartisan cosponsorship is notable but the sole cosponsor structure indicates limited legislative momentum. 2) The money trail: This bill does NOT authorize or appropriate any new spending. It changes the beneficiary cost-sharing structure only. Medicare still pays 80% of the fee schedule amount for CCM services (CPT codes 99490, 99491, 99487, 99489). The government's cost increases only to the extent that higher utilization occurs due to zero out-of-pocket costs. CBO would likely score this as increasing Medicare spending because the demand elasticity for zero-cost services is positive. However, there is no dollar figure in the bill text — the fiscal impact depends entirely on uptake scenarios. For context, Medicare spent approximately $4.5B on CCM services in 2023 (CMS data). A 15-25% utilization increase from removing cost-sharing would imply $700M-$1.1B in additional annual Medicare spending. 3) Structural winners and losers: The primary beneficiaries are Medicare beneficiaries with two or more chronic conditions (roughly 40M people). For companies, the winners are those with Medicare Advantage exposure and owned primary care assets: (Optum Care, UnitedHealthcare), $CVS (Aetna, Oak Street Health, MinuteClinic), (Humana's Medicare Advantage concentration is highest among peers at ~85% of earnings), (Molina's Medicaid-heavy mix limits exposure), and (Anthem/Elevance's Medicare Advantage business, though less concentrated than Humana). The losers are no specific companies — traditional Medicare FFS providers will see slightly higher volume but no margin change. For-profit hospital chains ($HCA, $THC, $UHS) see negligible direct impact because CCM is primarily physician-office based. 4) Competitive landscape: Medicare Advantage insurers already incentivize CCM enrollment for quality bonus payments (STARS ratings). The bill operationalizes an existing trend — MA plans already offer zero-cost CCM in many cases. The legislative impact would primarily affect Traditional Medicare (Part B), where beneficiaries face deductible and coinsurance today. This is a volume tailwind for independent primary care practices billing traditional Medicare, but those are largely private, not publicly traded. Publicly traded physician practice companies ($AGL, $AMED) have minimal CCM exposure. 5) Timeline: The bill is at the earliest stage — introduced and referred to committee. It needs full committee action in both Energy & Commerce and Ways & Means, then House floor vote, then Senate companion introduction and passage, then Presidential signature. The effective date of January 1, 2027, is feasible only if the bill passes by mid-2026. Given the current 119th Congress calendar (2025–2027), this bill is a low-probability candidate in its current form. A more likely path is inclusion as a Medicare Extenders package rider in late 2026. Market impact is minimal until either committee markup or bipartisan Senate companion emerges.